The World Desk · slice 04

Health & Bio Desk

Approvals, trials, and the research frontier — where a single regulatory decision reprices a molecule, a company, or a standard of care. This desk reads the health slice of the lattice, from FDA actions to the oncology literature.

$1.6T: annual sales of the global pharmaceutical market — industry estimates.

As of 2026-08-16 · live snapshot.

What the money says

Capital markets read as belief sensors — credit, volatility, and the desk’s own equity basket. Context, not a signal to act on.

10-year Treasury yields edged down 6 bps this week to 4.63% — the price of money moved down.

  • High-yield credit spread: 2.71% · flat 0 bps over 5 sessions · as of 2026-08-13
  • 10-year Treasury yield: 4.63% · down 6 bps over 5 sessions · as of 2026-08-13
  • Biotech basket (XBI): $157.41 · up 0.0% over 5 sessions · as of 2026-08-14

Public market data, cited as context — not investment advice.

Contracts & awards

From the federal public record (SAM.gov · USAspending): the money actually moving, not the press release about it.

Also tracked on this desk

Subjects whose coverage concentrates in this desk’s domains, counted from the committed corpus — story counts, not estimates.

colorectal cancer · 1,535 stories →KRAS · 347 stories →immunotherapy · 326 stories →ctDNA · 170 stories →wang · 116 stories →chen · 94 stories →zhang · 80 stories →pancreatic cancer · 80 stories →MSI-H · 61 stories →braf · 60 stories →g12d · 58 stories →eli lilly · 52 stories →

On the desk wire

Names native to this desk moving across the whole lattice right now. Click through for momentum, coverage, and the read.

In 8 domains · 34 mentions today

FDA

In 8 verticals across 7 domains

In 4 domains · 4 mentions today

Pfizer

In 4 verticals across 4 domains

In 4 domains · 5 mentions today

Bristol Myers Squibb

In 4 verticals across 3 domains

In 2 domains · 2 mentions today

Moderna

4.7x acceleration + migrated from biotech_pharma, corporate-finance to fda_decisions

In the coverage

The desk’s read of what its sources reported most recently. Distilled from 889 fresh items across 345 sources on this desk’s beat — the full lattice feeds every desk; these are the top reads.

Questions the desk is watching

KRAS: is the next trial readout a breakthrough or a setback?ctDNA: is minimal-residual-disease testing about to change the standard of care in colorectal cancer?Immunotherapy: where does the next approval most likely come?What is driving the current FDA trajectory?
THE HEALTH & BIO DESK BRIEF

What this desk sees, in your inbox: the record, the moves, and the read, written for managers whose portfolio is the world.

Informational only — not investment advice. Market-size figures are editorial estimates with sources as noted; contract and award lines are drawn from public federal records via our tracked pipelines.